Skip to main navigation Skip to search Skip to main content

Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)

  • Sanjay Popat
  • , Myung Ju Ahn
  • , Simon Ekman
  • , Natasha B. Leighl
  • , Suresh S. Ramalingam
  • , Thanyanan Reungwetwattana
  • , Shankar Siva
  • , Masahiro Tsuboi
  • , Yi Long Wu
  • , James Chih Hsin Yang
  • Royal Marsden NHS Foundation Trust
  • Institute of Cancer Research
  • Sungkyunkwan University
  • Karolinska Institutet
  • Princess Margaret Cancer Centre
  • Emory University
  • Mahidol University
  • Peter Maccallum Cancer Centre
  • University of Melbourne
  • National Cancer Center Japan
  • Guangdong Academy of Medical Sciences
  • National Taiwan University

Research output: Contribution to journal › Comment/debate

Abstract

While typesetting the articles the formatting of the Tables was incorrect. Now this has been corrected. The original article has been corrected.

Original languageEnglish
Pages (from-to)311
Number of pages1
JournalTargeted Oncology
Volume18
Issue number2
DOIs
StatePublished - Mar 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)'. Together they form a unique fingerprint.

Cite this